The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.
Ruud van der Noll
No relevant relationships to disclose
Joo Ern Ang
No relevant relationships to disclose
Agnes Jager
No relevant relationships to disclose
Serena Marchetti
No relevant relationships to disclose
Marja Mergui-Roelvink
No relevant relationships to disclose
Johann Sebastian De Bono
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Martijn Lolkema
No relevant relationships to disclose
Andre Brunetto
No relevant relationships to disclose
Hendrik-Tobias Arkenau
No relevant relationships to disclose
Maja J. De Jonge
No relevant relationships to disclose
Diane van der Biessen
No relevant relationships to disclose
Ilian Tchakov
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Karin Bowen
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Jan H. M. Schellens
No relevant relationships to disclose